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Abstract 
 
It had been thought that complement factor D (FD) is activated at the site of synthesis and 
only FD lacking a propeptide is present in blood. The serum of MASP-1/3(-/-) mice contains pro-FD 
and has markedly reduced alternative pathway activity. It was suggested that MASP-1 and MASP-3 
directly activate pro-FD, however other experiments contradicted this view. We decided to clarify 
the involvement of MASPs in pro-FD activation in normal, as opposed to deficient, human plasma 
and serum. 
Human pro-FD containing an APPRGR propeptide was produced in insect cells. We 
measured its activation kinetics using purified active MASP-1, MASP-2, MASP-3 as well as 
thrombin. We found all these enzymes to be efficient activators, while MASP proenzymes lacked 
such activity. Pro-FD cleavage in serum or plasma was quantified by a novel assay using 
fluorescently labeled pro-FD. Labeled pro-FD was processed with half-lives of about 3 and 5 hours 
in serum and plasma, respectively, showing that proteolytic activity capable of activating pro-FD 
exists in blood even in the absence of active coagulation enzymes. Our previously developed 
selective MASP-1 and MASP-2 inhibitors did not reduce pro-FD activation at reasonable 
concentration. On the other hand, at very high concentration, the MASP-2 inhibitor, which is also a 
poor MASP-3 inhibitor, slowed-down the activation. When recombinant MASPs were added to 
plasma only MASP-3 could reduce the half-life of pro-FD. 
Combining our quantitative data MASP-1 and MASP-2 can be ruled out as direct pro-FD 
activators in resting blood, however, active MASP-3 is a very likely physiological activator. 
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Introduction 
 
The complement system can be activated by three interconnected routes, the classical, the lectin and 
the alternative pathways (1). Activation of both the classical and the lectin pathways leads to the 
formation of the same C3 convertase, namely C4bC2a. Upon C3 cleavage C3b is generated that 
forms a transient complex with factor B (FB3). The FB component of the pro-convertase C3bB is 
then cleaved by factor D (FD) to produce the alternative pathway C3 convertase, C3bBb. Hence the 
alternative pathway serves as an important amplification loop for both the classical and the lectin 
pathways, however it can be also activated on its own by the “tick-over” mechanism (1). 
Components of the lectin pathway are (at least) five different pattern recognition molecules, 
MBL, H-ficolin (ficolin-3), L-ficolin (ficolin-2), M-ficolin (ficolin-1), and CL-LK, three MBL-
associated serine proteases, MASP-1, MASP-2, and MASP-3, and two MBL-associated proteins, 
MAp19 (sMAP), and MAp44 (MAP-1) (2-5). MASP-1 was shown to be the exclusive initiating 
enzyme during the activation of the lectin pathway (6-7), and together with MASP-2, they are both 
essential for the C4bC2a convertase formation. On the other hand the function of MASP-3 has been 
unclear. MASP-1 has relatively broad substrate specificity (8) and it was implicated that it has a 
role in several pro-inflammatory reactions (9-10) and coagulation (11). Both MASP-1 and MASP-3 
were suggested to participate in pro-FD conversion to FD (12-13) and it was speculated that even 
the proenzyme form of MASP-3 might be able to perform this process (13). 
FD is a key enzyme for the alternative pathway. Its sole natural substrate is FB in complex 
with C3b (14). When purified from blood only the active form can be retrieved (15-16), and it is 
accepted that FD is present predominantly in the active form in normal blood (15), although some 
pro-FD was reported to be present in diisopropyl-fluorophosphate-treated human plasma (17). It 
was speculated that FD might be activated before secretion by an unknown protease within the cells 
(18). In most cell types, expression of natural (19) or recombinant pre-pro-FD (i.e. a construct 
containing a signal peptide and the putative propeptide) resulted in accumulation of the active form 
in the cell culture supernatant (20) although a portion of the produced FD was proenzymic (20). On 
the other hand pro-FD was successfully produced in insect cells (21). In vitro, trypsin was found to 
be the best activator of pro-FD, while thrombin, kallikrein and plasmin can also activate it with 
varying efficiencies (21), however, the exact kinetic constants have not been determined. In MASP-
1/3(-/-) mice only pro-FD was found (12), and at first it was suggested that MASP-1 might be the 
enzyme responsible for pro-FD cleavage. However, reconstitution of the MASP-1/3(-/-) mouse 
serum with recombinant MASP-1 did not restore the alternative pathway (12). Later MASP-3 was 
also implicated as a possible pro-FD activator (13) suggesting a new role for this enzyme. On the 
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other hand alternative pathway activity was observed in MASP-1/3(-/-) human serum suggesting 
that neither MASP-1 nor MASP-3 is essential in pro-FD conversion to FD (22). Nevertheless this 
scientific debate brought to light some questions that for a long time have seemed to be resolved 
(23-24). Interestingly in Cfh(-/-)MASP-1/3(-/-) mice (deficient for factor H, MASP-1 and MASP-3) 
uncontrolled alternative pathway activation was present just like in Cfh(-/-) mice, suggesting that 
MASP-1 and -3 are not required for alternative pathway activity in Cfh(-/-) mice (25). In summary, 
the exact roles of MASPs in pro-FD activation have not been clarified yet, and additionally, we 
cannot exclude the possibility that significant differences may exist between human and mouse 
complement regarding pro-FD activation. 
In this study we aimed to clarify the role of MASPs in pro-FD activation in human blood. 
For this purpose we determined pro-FD cleavage rates using i) purified enzymes, ii) normal human 
serum and plasma in the absence and presence of specific MASP inhibitors and iii) normal human 
plasma with exogenous MASPs added. Our quantitative data (in combination) rule out all MASP 
proenzymes, as well as active MASP-1 and MASP-2 as direct pro-FD activators in resting blood, 
however, active MASP-3 is a likely physiological activator. The term “resting blood” in this paper 
refers to blood, in which neither the coagulation system nor the complement system is activated 
above the baseline level. 
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Materials and Methods 
 
Proteins and reagents 
 
Wild-type recombinant MASP-1, MASP-2, and MASP-3 catalytic fragments encompassing the 
CCP1-CCP2-SP domains (MASP-1cf, MASP-2cf, and MASP-3cf) were produced as described (26-
27, 7). MASP-1cf and MASP-2cf are obtained as active enzymes, while MASP-3cf is produced as a 
zymogen. Zymogen MASP-3cf was further purified on a YMC-Q30 (YMC Europe GmbH) anion-
exchange column (16 mm × 100 mm) by applying a 20-column-volume (CV) gradient of 60-200 
mM NaCl in 10 mM Tris-HCl pH=8.2. Active MASP-3cf was produced from the zymogen by 
cleavage using MASP-1cf, and then MASP-1cf was chromatographically removed as described 
(28). Active MASP-3cf was further purified on a YMC-Q30 column the same way as described 
above for the proenzyme. High purity active MASP-3cf was eluted as the first major peak at about 
150 mM NaCl. The stable zymogen variants, MASP-1cf R448Q and MASP-2cf R444Q, were 
prepared as described (7, 29). Human alpha-thrombin (Activity ≥2800 NIH units/mg protein, cat. 
no. T-1063) and bovine cationic trypsin (Activity ~10000 BAEE units/mg protein, cat. no. T-8003) 
were purchased from Sigma. FB and FD from human plasma were purchased from Merck 
(Calbiochem brand), and C3b was a gift from Prof. Mohamed R. Daha (Leiden University, Leiden, 
The Netherlands). The MASP-1 specific SGMI-1 and the MASP-2 specific SGMI-2 inhibitors were 
prepared according to Héja et al. (30). Blood was drawn from 7 healthy volunteers into Vacutainer 
serum tubes (BD Diagnostics) to produce fresh serum, and into Vacutainer citrate tubes (BD 
Diagnostics) to produce fresh plasma. After centrifugation serum samples were pooled and kept 
frozen in aliquots at -70 oC to produce normal human serum. Human plasma was also prepared by 
centrifugation, pooled, and kept at -70 oC in aliquots. Cy3-NHS ester and Cy5-NHS ester was 
purchased from GE Healthcare. Acetonitrile and ultrapure (LC-MS grade) water for mass 
spectrometric analysis were purchased from Merck (Darmstadt, Germany). 
 
Human pro-FD expression and purification 
 
The C-terminally poly-histidine-tagged (His6) human pre-pro-FD encoding DNA was purchased as 
a synthetic gene from Entelechon GmbH (Regensburg, Germany). The coding sequence was 
manually codon optimized for expression in Sf9 cells taking into account the Spodoptera frugiperda 
codon usage frequencies found in the Codon Usage Database (http://www.kazusa.or.jp/codon/). The 
clone encodes the human signal peptide, the activation peptide and the mature human FD 
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polypeptide chain followed by a His6-tag. The gene sequence and the translation are provided as a 
supplement (supplementary Table S1). The PstI-EcoRI fragment of the synthetic gene was 
subcloned into the pVL1392 (BD Biosciences) transfer vector. The resulted pVL1392_hu-pre-pro-
FD-H6 plasmid was used to co-transfect Sf9 cells with linearized AcNPV baculovirus DNA using 
the BaculoGoldTM transfection kit (BD Biosciences). The recombinant baculovirus was amplified 
by several rounds, and secreted protein was verified by Western blotting with a monoclonal anti 
human complement FD antibody (Thermo Scientific, cat. no. GAU 010-04-02). For large scale 
expression of recombinant pro-FD-H6 in Spodoptera Frugiperda Sf9 cells (BD Biosciences), a 100-
mL cell suspension (cell density of 2×106 cells/mL) in Insect-Xpress protein-free medium (Lonza) 
was infected with the recombinant baculovirus strain by adding 1.5 mL (~2×108 pfu/mL) of the 
virus stock. After 3.5 days of incubation at 27 oC, the culture supernatant was collected by 
centrifugation (500 g, 5 min) for purification. 
The recombinant human pro-FD-H6 containing supernatant was gel-filtrated on a Sephadex 
G-25 (GE Healthcare) 50 mm × 195 mm column in 10 mM imidazole, 250 mM NaCl, pH=7.5 
buffer. Fractions containing the desired protein were combined and applied to a 16 mm × 60 mm 
Ni-NTA Superflow (QIAGEN) column and eluted with a linear gradient of 10-250 mM imidazole, 
in a 250 mM NaCl, 50 mM NaH2PO4, pH=7.5 buffer. The pro-FD-H6 containing fractions were 
combined, and dialyzed overnight excessively against 20 mM NaH2PO4, pH=6.8 at 4 oC, then pro-
FD-H6 was applied to a 16 mm × 125 mm YMC-BioPro S30 (YMC Europe GmbH) cation-
exchange column equilibrated with 20 mM NaH2PO4, pH=6.8 buffer, and eluted with a 50-350 mM 
NaCl linear gradient in the same buffer. During this chromatographic step two separable forms of 
pro-FD-H6 were observed. The first eluted peak was designated as “A”, and the second peak, the 
major form, was designated as “B”. Fractions were assayed for purity by SDS-PAGE, and the 
appropriate fractions of the two forms were combined separately, then concentrated on 10-kDa 
cutoff concentrators to about 1 mg/mL and stored frozen in aliquots. The “B” form represents intact 
human pro-FD-H6 (see the next section) and the term “pro-FD” will refer to this form unless 
otherwise stated. The concentration of pro-FD was calculated based on the extinction coefficient 
ε280 = 28 460 M-1 cm-1, and a molecular mass of 25.8 kDa. 
 
Characterization of pro-FD by mass spectrometry 
 
Initial MALDI-TOF mass spectrometry (MS) analysis exhibited that the “B” form is consistent with 
the molecular weight of pro-FD-H6, and the “A” form is degraded probably at the N-terminus (data 
not shown). The “B” form of recombinant human pro-FD was further analyzed by liquid 
chromatography (HPLC) coupled to electrospray (ESI) quadrupole time-of-flight (QTOF) mass 
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spectrometry. 10 µL of the sample was desalted and separated without pretreatment using reversed 
phase chromatography on a Dionex U3000 RSLC system (Thermo Scientific, Dreieich, Germany). 
The separation was performed on a Poroshell 300SB C18 column (1 mm × 75 mm; 5 µm particle 
diameter, 300 Å pore size, Agilent Technologies) at 75 oC and 200 µL/min applying a 40-minute 
linear gradient with varying slopes. In detail, the gradient steps were applied as follows (minute / % 
Eluent B): 0/5, 3/5, 5/15, 20/32, 22/36, 29/50, 31/100, 34/100, 36/5, 40/5. Eluent B was acetonitrile 
with 0.1 % formic acid, and solvent A was water with 0.1% formic acid. To avoid contamination of 
the mass spectrometer with buffer salts, the HPLC eluate was directed into waste for the first two 
minutes. Continuous mass spectrometric analysis was performed using a quadrupole time-of-flight 
mass spectrometer (Maxis UHR-TOF, Bruker, Bremen, Germany) with an ESI source operating in 
positive ion mode. Spectra were taken in the mass range of 600-2000 m/z. External calibration was 
applied by infusion of tune mix via a syringe pump during a short time segment at the beginning of 
the run. Raw MS data were lock-mass corrected (at m/z 1221.9906) and further processed using 
Data Analysis 4.1 and MaxEnt Deconvolution software tools (Bruker, Bremen, Germany). 
 
Preparation of active FD from pro-FD and testing its activity 
 
For producing active FD from its zymogen form, pro-FD was incubated with 1/1000 amount of 
trypsin (by weight) at 37 oC for 25 minutes in 20 mM NaH2PO4, ~300 mM NaCl, pH=6.8 buffer. 
The reaction was attenuated by 10-fold dilution with ice-cold equilibration buffer, then the sample 
was applied immediately to a 5 mm × 58 mm SP Sepharose High Performance (GE Healthcare) 
column equilibrated with 20 mM NaH2PO4, 200 mM NaCl, pH=6.8 buffer, and eluted with a 200-
550 mM NaCl linear gradient in the same buffer. Fractions were assayed for purity by SDS-PAGE, 
then selected fractions were combined and concentrated on 10 kDa cutoff concentrators to about 
0.5-1 mg/mL, then stored frozen in aliquots. The concentration of FD was calculated based on the 
extinction coefficient ε280 = 28 460 M-1 cm-1, and a molecular mass of 25.2 kDa. 
100 µg/ml C3b and 100 µg/ml Factor B were incubated with 50 µg/ml recombinant FD or 
plasma FD in 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, pH=7.5 at 37 oC. Samples were 
taken at 0, 0.5, 1, 2, 4, 6, 24 hours. Reactions were stopped by 2-fold dilution with SDS-PAGE 
sample buffer and heating for 2 mins at 95 oC. Samples were then analyzed by SDS-PAGE under 
reducing conditions. 
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Pro-FD cleavage assay by cation exchange chromatography 
 
Pro-FD was dialyzed overnight excessively against 140 mM NaCl, 50 mM HEPES, 0.1 mM EDTA, 
pH=7.4, then concentrated to 0.5-1 mg/mL and stored frozen in aliquots. The cleavage assays were 
performed in the same buffer at 10 or 20 µM final pro-FD concentration, and the samples were 
incubated for up to 3 hours at 37 oC. Trypsin, thrombin, active MASP-1cf, active MASP-2cf, active 
MASP-3cf, zymogen MASP-1cf R448Q, zymogen MASP-2cf R444Q, and zymogen MASP-3cf 
were applied at 0.20 nM, 635-955 nM, 33-68 nM, 13.5 nM, 30-61 nM, 7.0 µM, 6.5 µM, and 5.3-9.4 
µM final concentrations, respectively, and samples were taken at every 30-40 mins. The reaction 
was stopped by 30-fold dilution with ice-cold equilibration buffer, then the sample was applied 
immediately to a 4.6 mm × 50 mm YMC-BioPro SP-F non-porous high pressure cation exchange 
column (YMC Europe GmbH) equilibrated with 20 mM NaH2PO4, 100 mM NaCl, pH=6.8 buffer, 
and eluted with a 100-450 mM NaCl linear gradient in the same buffer at 0.8 mL/min ensuring 
rapid analysis. The observed first order rate constant (kobs) was determined by nonlinear regression 
using the AUC = AUCo×exp(-kobs×t) equation, where AUC is the integrated area of the pro-FD 
peak, and AUCo is the area at the zero time point. In order to make the rate constants of the different 
reactions comparable, kobs/[E]T values were calculated, where [E]T is the total enzyme 
concentration. The kobs/[E]T value can be considered as an approximation of the catalytic efficiency 
(kcat/KM) according to the Michaelis-Menten kinetics when the substrate concentration is lower then 
the KM. 
 
Preparation and purification of Cy3-pro-FD and Cy5-FD 
 
For fluorescent labeling pro-FD and FD we used Cy3 and Cy5 CyDye monoreactive NHS Esters 
(GE Healthcare). Dried dyes were dissolved to 1 mg/ml in anhydrous DMF (Merck), and stored 
frozen in aliquots. Labeling reactions were performed in 20 mM NaH2PO4, ~300 mM NaCl, pH=6.8 
buffer with 10:1 dye to protein molar ratio and were incubated in the dark for 4 hours at room 
temperature, then overnight at 4 oC. The reactions were stopped by adding 1/10 volume of 1 M 
Tris-HCl pH=8 buffer, and after 30-fold dilution with ice-cold equilibration buffer samples were 
applied to a 5 mm × 55 mm YMC-BioPro S30 (YMC) column equilibrated with 20 mM NaH2PO4, 
pH=6.8 buffer, and eluted with a 0-350 mM NaCl linear gradient in the same buffer. Single-labeled 
Cy3-pro-FD had an A549/A280 ratio of about 4, and single-labeled Cy5-FD had an A649/A280 ratio of 
about 6. Fractions were assayed homogeneity by SDS-PAGE, then selected fractions containing 
single-labeled proteins were combined, then concentrated on 10 kDa cutoff concentrators to 1 
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mg/mL and stored frozen in aliquots. The concentrations of Cy3-pro-FD, and Cy5-FD were 
calculated based on the extinction coefficients of Cy3 (ε549nm = 150 000 M-1cm-1), and Cy5 (ε649nm = 
250 000 M-1cm-1), and a molecular masses of 26.5 or 25.9 kDa, respectively. 
 
Cy3-labeled pro-FD cleavage in serum and plasma samples 
 
Conversion of Cy3-labeled pro-FD into Cy3-FD in serum or plasma was monitored as follows. 5 
µL of 1 mg/mL Cy3-pro-FD was added to 50 µL of normal human serum or citrated plasma and the 
mixtures were incubated at 37 oC for 24-26 hours. Samples were withdrawn at every hour in the 
first 8 hours then an overnight (24-26 h) sample was collected. 
In order to test the contribution of the thrombin-content of serum to convert pro-FD into FD 
we added 1 mL of serum to a Vacuette Hirudin Blood Tube (Roche) containing more than 45 µg 
hirudin. Cy3-pro-FD conversion was tested on the same batch of hirudin-treated and untreated 
serum as above. 
In order to test the impact of MASP inhibitors on pro-FD conversion into FD we added them 
to serum or plasma prior to the addition of labeled pro-FD. 1 µL of SGMI-1 (15 µM final 
concentration) was added to 50 µL of normal human serum or citrated plasma and the mixtures 
were incubated for 10 mins at room temperature, then 5 µL of 1 mg/mL Cy3-labeled pro-FD was 
added and the mixtures were incubated at 37 oC for 24-26 hours. Samples were withdrawn at every 
hour in the first 8 hours then an overnight (24-26 h) sample was collected. 1 µL of appropriately 
diluted SGMI-2 (15 or 1 or 0.1 µM final concentration) was added to 50 µL of normal human 
serum or citrated plasma and the mixtures were incubated for 10 mins at room temperature, then 5 
µL of 1 mg/mL Cy3-labeled pro-FD was added and the mixtures were incubated at 37 oC for 24-26 
hours. Samples were withdrawn at every 1-2 hours in the first 8-14 hours and finally an overnight 
(24-26 h) sample was collected. 
In order to test the impact of exogenously provided MASPs on pro-FD conversion into FD 
we added 1 µL of appropriately diluted MASP-1cf, MASP-2cf or MASP-3cf (50-200 nM final 
concentration) to 50 µL of citrated normal human plasma and the mixtures were incubated for 10 
mins at room temperature, then 5 µL of 1 mg/mL Cy3-labeled pro-FD was added and the mixtures 
were incubated at 37 oC for up to 24 hours. Samples were withdrawn at every hour in the first 7 
hours and finally an overnight (24-26 h) sample was collected, except when 200 nM MASP-3cf was 
used, where samples were withdrawn at every 15 minutes for up to 2 hours. 
All reactions were stopped by 10-fold dilution with SDS-PAGE sample buffer and heating 
for 2 mins at 95 oC. Cy5-labeled FD was diluted to 3.6 ng/µL with SDS-PAGE sample buffer then 
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treated for 2 mins at 95 oC. 2 µL of the cleavage assay samples containing 18 ng Cy3-labeled 
protein were mixed with 5 µL of diluted Cy5-labeled FD (18 ng), the mixed samples were run on 
SDS-PAGE under reducing condition, and the gels were scanned with Typhoon (GE Healthcare) 
laser scanner. Band intensities were quantified by densitometry. Because the two bands were 
partially overlapping only the time point, where the intensity of the Cy3-pro-FD band equaled that 
of the Cy3-FD band, could be reliably determined on a particular gel. This time point is considered 
to be the half-life of Cy3-pro-FD. When the intensity of the Cy3-pro-FD band was higher at a given 
time point and lower in the subsequent time point than the intensity of the Cy3-FD band, we used 
interpolation. 
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Results 
 
Expression and characterization of His-tagged human pro-FD 
 
Human pre-pro-FD was expressed in insect cells using a baculovirus vector as described in the 
Materials and Methods. The construct contained the human signal sequence and a C-terminal His6-
tag to aid purification. As previously described, insect cells produce predominantly pro-FD (21). 
Under our expression conditions we obtained two major variants eluting in different peaks termed 
“A” and “B” during the last cation exchange step. Preliminary MALDI-TOF analysis exhibited that 
the “B” form is consistent with the molecular weight pro-FD-H6, and the “A” form is probably 
degraded (data not shown). Further analysis by HPLC-ESI-QTOF MS (Fig. 1) showed that the 
molecular weight of the “B” form is consistent with an N-terminal propeptide sequence of 
APPRGR. In all subsequent experiments we used the “B” form of pro-FD-H6, hereafter simply 
termed as pro-FD. Since our major goal was to detect pro-FD activation by various serine proteases, 
which involves cleavage at the N-terminus, the small tag at the C-terminus most likely does not 
interfere with this reaction. We also converted our pro-FD into active FD by trace amounts of 
trypsin and purified it to remove the trypsin activity. The produced active enzyme cleaved FB-C3b 
in a similar fashion as the purchased control FD purified from human plasma (data not shown). 
 
In vitro cleavage-rates of pro-FD by various proteases 
 
Pro-FD can be very effectively activated by trypsin in vitro (21), therefore we also used bovine 
cationic trypsin as a highly active control protease in our assay system. Samples of pro-FD (10-20 
µM) were treated with trypsin, thrombin, MASP-1cf, MASP-2cf, MASP-3cf, and also the 
proenzymic forms of all three MASPs at 37 oC. The cleaving enzymes were used at concentrations 
suitable to produce approximately 80% consumption of pro-FD in less than 3 hours, as determined 
from preliminary experiments. Aliquots containing 10 µg total pro-FD + FD were withdrawn at 30-
40 minute periods, diluted 30-fold with ice-cold binding buffer and analyzed immediately on a 
small cation exchange column as described in the Materials and Methods. The peak corresponding 
to pro-FD gradually disappears while a new peak with increasing intensity corresponding to FD 
appears over time (Fig. 2). Fitting the AUC (area under the curve) values of the pro-FD peak versus 
time (Fig. 3) yielded kobs values for each reaction. Normalized by the enzyme concentrations the 
cleavage efficiencies can be compared, as summarized in Table I. The highest cleavage rate, by far, 
is produced by trypsin, whereas active MASP-1cf, MASP-2cf, MASP-3cf, and thrombin are fairly 
 12 
efficient activators of pro-FD. Proenzymic MASPs have either marginal (R448Q MASP-1cf), or no 
activity at all. 
 
Cleavage rates of pro-FD in human serum and plasma 
 
In order to model pro-FD cleavage in human blood we developed a novel experimental setup that is 
suitable to monitor pro-FD cleavage in a complex mixture. We labeled pro-FD with Cy3 dye and 
followed its cleavage in normal human serum or citrated plasma. In both cases Cy3-labeled pro-FD 
was added at 3.5 µM final concentration, and its cleavage was followed at 37 oC.  Adding the 
concentrated labeled protein to serum or plasma caused only a minimal (10%) dilution of the 
original serum or plasma samples. Aliquots were withdrawn typically at every hour, then 
immediately diluted 10-fold with SDS-PAGE sample buffer and heated for 2 mins at 95 oC to stop 
the reactions. Portions of the treated samples containing 0.18 µL of the original serum or plasma 
and about 18 ng total of Cy3-pro-FD + Cy3-FD were loaded per lane and analyzed by SDS-PAGE 
(Fig. 4). Consumption of the Cy3-pro-FD band was apparent over time and a new band appeared 
with a slightly higher mobility. In most gels the SDS-PAGE samples containing Cy3-pro-FD + 
Cy3-FD (18 ng total) were mixed with samples containing 18 ng of Cy5-FD to allow multiplexing 
and unambiguous distinction of the uncleaved and cleaved forms (Fig. 4A). Our results showed that 
Cy3-pro-FD was converted to Cy3-FD in serum with a half-life of about 3 hours, and in plasma 
with a half-life of about 5 hours. The difference is probably due to thrombin and possibly other 
coagulation enzymes present in serum. Preliminary experiments with hirudin-treated serum 
revealed that the half life of Cy3-pro-FD increased by about half an hour compared to normal serum 
(data not shown) hence the difference between serum and plasma can only be partially attributed to 
the impact of thrombin. 
Most importantly Cy3-pro-FD was converted into Cy3-FD in human plasma, as well, 
suggesting that there is a proteolytic activity capable of activating pro-FD in human blood, even in 
the absence of active coagulation enzymes. The activator in plasma is likely to be the physiological 
pro-FD activator in resting blood where activation of the coagulation cascade does not occur. 
In order to assess whether any of the MASPs could be potential physiologic pro-FD 
activator, based on the kobs/[E]T values obtained from in vitro cleavage experiments, we calculated 
corresponding MASP concentrations required to produce the observed pro-FD half-lives of about 3, 
and 5 hours (Table II). These data suggest that each MASP could be considered as a potential 
activator, but only if a significant proportion is already activated. 
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Cleavage of pro-FD in human serum and plasma in the presence of MASP inhibitors 
 
Previously we have developed specific inhibitors for MASP-1 and MASP-2 (30). SGMI-1 is a 
specific MASP-1 inhibitor with a Ki of about 7 nM, while SGMI-2 is a highly selective MASP-2 
inhibitor with a Ki of about 6 nM. We observed that SGMI-2 also inhibits MASP-3, although very 
poorly, with a Ki of about 5 µM (6). We used these inhibitors at various concentrations to assess 
their effects on pro-FD activation in serum and plasma. 
SGMI-1 did not affect the conversion of Cy3-pro-FD to Cy3-FD even at the highest 
concentration (15 µM) applied (Fig. 5 and Table III) neither in plasma nor in serum. This 
experiment unambiguously rules out MASP-1 as a direct pro-FD activator. Since in vitro active 
MASP-1 is a potent pro-FD activator, these results also imply that there is no significant amount of 
active MASP-1 in resting blood. 
At 100 nM, which is well above the Ki for MASP-2, SGMI-2 had no effect at all and even 1 
µM of SGMI-2 had only small effect (Fig. 5 and Table III). This ruled out MASP-2 as well as direct 
pro-FD activator. Although we applied SGMI-2 primarily because it inhibits MASP-2, calculations 
presented in Table II would imply that essentially all MASP-2 would have to be in the active form 
to produce the measured Cy3-pro-FD half-life in plasma. This is in contrast with the observation 
that MASP-2 circulates as a proenzyme in the blood (32). So the results are coherent with all 
calculations and previous observations. 
However, to our surprise, at high (15 µM) inhibitor concentration SGMI-2 significantly 
slowed down Cy3-pro-FD conversion both in serum and plasma (Fig. 5 and Table III). The effect 
was more pronounced in plasma. The difference between serum and plasma can be explained by the 
effect of thrombin and possibly other coagulation enzymes, which are not inhibited by SGMI-2 (6). 
On the other hand, the measured concentration dependence is highly consistent with the Ki value of 
5 µM of SGMI-2 for MASP-3 (6). 
In summary, our experiments so far rule out MASP-1 and MASP-2 as physiological pro-FD 
activators in resting blood, suggesting that some other protease or proteases are responsible for this 
activity. Our observations are consistent with active MASP-3 to be such an enzyme, but also imply 
that for such a role significant portion of MASP-3 should be in active form even in resting blood. 
These assumptions require further experiments to prove unambiguously. 
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In order to further characterize the effect MASPs on pro-FD conversion into FD we added MASP-
1cf, MASP-2cf, or MASP-3cf to normal human plasma at 50-200 nM concentrations. Since we 
have shown before that only the active forms have considerable activity toward pro-FD (Tables I 
and II) we used active MASPs. At 200 nM final plasma concentration exogenously provided 
MASP-1 and MASP-2 did not reduce the half-life of Cy3-pro-FD at all, in spite of the fact that both 
can cleave pro-FD in a purified system. This suggests that both active enzymes are rapidly 
inactivated probably by C1-inhibitor and antithrombin. On the other hand MASP-3 reduced the 
half-life of Cy3-pro-FD significantly in a dose-dependent fashion (Fig 6 and Table IV). At 50 nM 
MASP-3cf the half-life was reduced to 2 hours, while at 200 nM to less than half an hour, 
suggesting that MASP-3 is not inhibited and indeed capable of cleaving pro-FD in the complex 
matrix of human plasma. 
Summing up, the experiments in the presence of exogenously added MASPs reinforced our 
assumption that MASP-3 can indeed convert pro-FD into FD in plasma, and among lectin pathway 
proteases only MASP-3 can be considered as the pro-FD activator of resting blood. 
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Discussion 
 
Controversy in the literature regarding the role of the lectin pathway, in particular the involvement 
of MASP-1 and MASP-3 (12-13, 22), in the activation of the alternative pathway led us to take a 
closer look at the impact of MASPs on pro-FD cleavage. For this purpose we already had highly 
purified recombinant catalytic fragments of all MASPs, both in proenzymic and active form, and 
highly selective inhibitors for MASP-1 and MASP-2. 
We also needed pro-FD that we produced in the baculovirus insect cell expression system. It 
had been previously reported that in this expression system, pro-FD is released into the culture 
medium in two zymogen forms with respective activation peptides AAPPRGR and APPRGR (21) 
in a 2:1 ratio. The high mass resolution and accuracy attained by the ESI-QTOF approach enabled 
us to unambiguous identify the produced proteins. In our experiments, the vast majority of pro-FD 
purified from insect cell culture medium contained the APPRGR activation peptide. This finding is 
in agreement with the predicted signal peptide cleavage site (33). Notably, contrary to what was 
found earlier, the other form having an additional N-terminal alanine (AAPPRGR) could be barely 
detected. It should be noted, however, that Yamauchi and colleagues seem to have used a shortened 
signal peptide (21) while we used the natural human signal peptide. So apparently APPRGR 
represents the dominant natural propeptide. 
In order to compare their inherent capacity to activate pro-FD first we have determined the 
cleavage rate constants for all MASPs. Interestingly there was only a slight difference among the 
active MASPs indicating that, at least in vitro, they are all capable of activating pro-FD. The highly 
purified zymogen forms had zero (MASP-2 and MASP-3) or marginal (MASP-1) pro-FD cleaving 
activity. These results indicate that the main question is not which MASPs have the ability to cleave 
pro-FD, but rather which ones have sufficiently high concentration in the active form to carry out 
such cleavage in resting blood. On the other hand during lectin pathway activation, when all the 
three MASPs are present in their active form, activation of pro-FD may be accelerated considerably. 
In order to model the physiologic situation, we measured the half-lives of labeled pro-FD in 
normal human plasma and serum. The half-life was shorter in serum indicating that coagulation 
enzymes, including thrombin, may be able to convert pro-FD into FD. In complement assays serum 
is used routinely. Our results indicate that one should be careful when drawing conclusion on the 
natural pro-FD activating capacity of an individual or model animal by using serum samples (23-
24), as low-level activation of pro-FD might occur by backup enzymes in the serum even in the 
absence of the natural pro-FD activator of the resting blood. In this respect it is noteworthy that FD 
deficient mouse serum reconstituted to less than 1% of the normal FD level restored 23% of the 
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alternative pathway activity (34), suggesting that the normal level of FD is not limiting, as opposed 
to previous results (15). 
In resting blood the coagulation cascade is not activated, and therefore plasma experiments 
may represent a better model for the normal physiological pro-FD conversion than serum 
experiments. Because labeled pro-FD was converted to FD in plasma with a half-life of about 5 
hours, it is reasonable that a proteolytic activity exists in resting blood that converts pro-FD to FD. 
The labeled pro-FD concentration that we used was 3.5 µM, because such high concentration was 
necessary for reliable detection. This value is significantly higher than the physiological FD 
concentration (80 nM) (15), distorting unfavorably the enzyme to substrate ratio, therefore it is 
plausible that the pro-FD conversion rate in the circulation is higher providing a significantly 
shorter half-life than the measured approximately 5 hours. Another contributing factor could be the 
“buffer effect” of citrated plasma. It is also possible that in the presence of Ca2+ the main converting 
enzyme has a higher activity. On the other hand, in plasma further activation of lectin-pathway 
proteases and coagulation enzymes above the baseline level can be excluded, therefore we used 
both serum and plasma in order to evaluate the effects of our MASP inhibitors. 
When we added a MASP-1 specific inhibitor (SGMI-1, Ki ~ 7 nM) to serum or plasma at 15 
µM final concentration the pro-FD conversion rate was no different from the inhibitor-free values. 
It is noteworthy that SGMI-1 inhibits both active (30) and proenzymic MASP-1 (7). Based on these 
observations we unambiguously ruled out MASP-1 as a direct pro-FD activator in resting blood. If 
MASP-1 is somehow involved in pro-FD maturation, its contribution can only be indirect e.g. 
through MASP-3 activation (7, 13). 
To our surprise, SGMI-2, a highly selective MASP-2 inhibitor with a Ki of 6 nM, did slow-
down pro-FD conversion both in serum and plasma, although only at high inhibitor concentration 
(15 µM). The effect was more pronounced in plasma. Here we became suspicious, because 
according to our calculations essentially all MASP-2 would have to be in the active form to produce 
a 5-hour half-life for labeled pro-FD in plasma. This is in sharp contrast with previous observations 
that MASP-2 exists in the proenzyme form in resting blood (32). Importantly, SGMI-2 also inhibits 
MASP-3 (6), but only quite poorly with a Ki of about 5 µM. When we examined how pro-FD 
cleavage rate in plasma depends on SGMI-2 concentration, we found that 1 µM SGMI-2 had a 
minor effect, and 100 nM SGMI-2 had no effect at all. This concentration dependence was more 
consistent with the involvement of an enzyme inhibited by SGMI-2 with a Ki value in the 
micromolar range. We note that MASP-3 is such an enzyme. Nevertheless, based solely on these 
results, we cannot yet identify MASP-3 as the exclusive pro-FD activator in resting blood. 
Experiments with exogenously added MASPs further support the idea that MASP-3 is the 
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physiological pro-FD activator, as we demonstrated that among MASPs only MASP-3 was capable 
of reducing the half-life of labeled pro-FD is plasma. 
Our observations support the view of Takahashi et al. (24, 35) and Iwaki et al. (13), who 
proposed that MASP-3 acts as a pro-FD activator. In contrast to Iwaki et al (13) who stated that 
even zymogen MASP-3 might activate pro-FD, we have shown that only active MASP-3 can carry 
out that cleavage. When Dahl and colleagues (36) first isolated MASP-3 containing complexes, the 
majority of MASP-3 appeared to be in the active (two-chain) form, even though they used protease 
inhibitors during the isolation. It is, however, not clear that activation of MASP-3 occurred during 
the isolation, or MASP-3 associated with MBL was already active. Our experiments suggest that for 
MASP-3 to be the major pro-FD activator a significant portion (at least about 10 nM) has to be in 
the active form in plasma to provide the observed cleavage rate. It will require further investigations 
to accurately determine what percentage of MASP-3 is actually present in resting blood in the 
active form. It is also an intriguing question how zymogen MASP-3 is activated in the absence of a 
lectin pathway activating surface. One possibility is that fluid phase activation of lectin pathway 
proteases occurs slowly at a constant rate, but active MASP-1 and MASP-2 are rapidly inactivated 
by their natural inhibitors like C1-inhibitor and antithrombin (37). This assumption is supported by 
the presence of MASP-1-C1-inhibitor and MASP-1-antithrombin complexes in normal serum and 
plasma (38). Importantly, as active MASP-3 is not inhibited by C1-inhibitor (39), or any other 
identified serpin, it could slowly accumulate in such a scenario. Our observations with exogenously 
added MASPs support such a mechanism. When recombinant active MASP catalytic fragments 
were added to plasma, only MASP-3 reduced the half-live of labeled pro-FD, indicating that while 
MASP-1 and -2 are inactivated rapidly MASP-3 remains active. 
Taken together, we have shown that in vitro the active serine proteases generated during 
activation of the coagulation (tested with thrombin) and the complement cascades (MASP-1, -2 and 
-3) can cleave pro-FD with comparable efficiencies. In serum, the contribution of the coagulation 
proteases may be significant. Furthermore in resting blood MASP-1 and MASP-2 cannot be direct 
activators of pro-FD. 
On the other hand, we have unambiguously demonstrated that at least one protease capable 
of activating pro-FD exists in normal human plasma. While further experiments are needed to 
unequivocally identify the physiological and perhaps exclusive pro-FD activator in resting blood, 
here we provided important evidences that activated MASP-3 is the likely candidate (Fig. 7). 
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Figures 
 
FIGURE 1. High resolution deconvoluted ESI-QTOF MS spectrum of recombinant pro-FD-H6 in 
positive mode. The measured dominant mass peak (I.) was found to be in perfect agreement with 
the calculated mass of the intact protein with an N-terminal propeptide sequence APPRGR 
(25,838.15 Da). A small peak (II., ∆= -17 Da) can be assigned to succinimide formation within the 
same protein. A minor peak (25909.16 Da) is consistent with the AAPPRGR propeptide, but it 
constitutes only a minor fraction. Importantly, the analysis of the entire spectrum (10-30 kDa, see 
insert) clearly showed that the purified pro-FD-H6 is highly homogenous and essentially free from 
contamination or degradation. 
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FIGURE 2. Detection of pro-FD cleavage by various proteases using analytical cation exchange 
chromatography. Typically 10 µM pro-FD was incubated in the presence of the activating proteases 
at 37 oC at physiological salt concentration and pH for up to 3 hours. Samples containing a total of 
10 µg pro-FD + FD were removed periodically and analyzed immediately on an analytical cation 
exchange column. 10 µg pro-FD (A) and 10 µg FD (B) served as controls. The cleavage by MASP-
1cf (C) and MASP-3cf (D) are shown as examples. AUC (area under the curve ) values were 
determined by integrating the pro-FD peak, and the data were fitted as shown on Fig 3. 
 26 
 
 
FIGURE 3. Fitting of the measured data to determine the cleavage rates of pro-FD by various 
proteases. The observed first order rate constants (kobs) were determined by nonlinear regression 
using the AUC = AUCo×exp(-kobs×t) equation, where AUC is the integrated area of the pro-FD 
peak, and AUCo is the area at the zero time point (i.e. pro-FD control). The calculated kobs/[E]T 
values are found in Table I, where [E]T is the total enzyme concentration. Data obtained from pro-
FD cleavage by MASP-1cf (A) and MASP-3cf (B) are shown as examples. 
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FIGURE 4. Determination of the half-life of Cy3-pro-FD in serum and plasma. Cy3-pro-FD was 
added to human serum or plasma causing only minimal dilution and the mixture was incubated at 
37 oC. SDS-PAGE was performed under reducing conditions as described in the Materials and 
Methods. A sample containing a total of 18 ng Cy3-pro-FD + Cy3-FD and 0.18 µL serum or plasma 
was applied to each lane. Because of the small difference in mobility, samples were usually 
multiplexed with 18 ng Cy5-FD per lane. Gels were scanned by a Typhoon laser scanner at 
excitation and emission wavelengths characteristic for Cy3 and Cy5 consecutively. The top panel 
(A) shows the overlay of the Cy3 (colored red) and Cy5 (colored green) channels for a gel with 
serum samples. Cy3-pro-FD disappeared over time indicating cleavage, and the produced Cy3-FD 
co-migrated with the Cy5-FD resulting in a yellowish-green band. The Cy3 channel of a 
representative gel out of 5 parallels with serum (B) and plasma (C) samples are shown on the 
bottom panels. The half-life of Cy3-pro-FD is considered to be the time point where the intensity of 
the Cy3-pro-FD band equals that of the Cy3-FD band, as explained in more detail in the Materials 
and methods. 
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FIGURE 5. Determination of the half-life of Cy3-pro-FD in plasma in the presence of inhibitors. 
Experiments were carried out in the presence of SGMI-1, a MASP-1 specific tight-binding inhibitor 
(A), or SGMI-2, a tight-binding inhibitor of MASP-2, and also a poor inhibitor of MASP-3 (B and 
C) at various concentrations as indicated. The experiment was carried out essentially as described 
under Fig.4. Panels A, B, and C depict representative gels out of 2, 4, and 5 parallels, respectively. 
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FIGURE 6. Determination of the half-life of Cy3-pro-FD in plasma in the presence of exogenously 
added MASPs. MASP-1cf (A), MASP-2cf (B) and MASP-3cf (C) were applied at 200 nM final 
concentration. Only MASP-3 reduced the half-life of Cy3-pro-FD compared to normal plasma. The 
experiment was carried out essentially as described under Fig.4. Representative gels out of 2 
parallels are shown. 
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FIGURE 7. The suggested scenarios of pro-FD activation. The physiologically most important 
mechanism is the one in resting blood, because in normal blood most FD is present in the active 
form. In deficiencies, where a patient has mostly pro-FD, the backup mechanisms might contribute 
to pro-FD activation in case of injury or infection, or in vitro when serum is used for complement 
assays for testing. The most likely candidate to activate pro-FD in resting blood is active MASP-3, 
but further experiments are needed to unambiguously prove this assumption. 
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Table I 
Activation rates of pro-FD by various proteases 
enzyme a kobs / [E]T (M-1 s-1) 
bovine trypsin b 1.5 ± 0.5 × 106 
thrombin b, c 4.6 ± 1.2 × 102 
wt MASP-1cf (active) d 3.9 ± 1.2 × 103 
wt MASP-2cf (active) b 7.2 ± 0.4 × 103 
active wt MASP-3cf  d 4.7 ± 1.2 × 103 
R448Q MASP-1cf (zymogen) b 18 ± 2 
R444Q MASP-2cf (zymogen) e n. d. 
zymogen wt MASP-3cf  e n. d. 
a The kobs/[E]T value can be considered as an approximation of the catalytic 
efficiency (kcat/KM) according to the Michaelis-Menten kinetics when [S]<KM. 
b
 Average ± range (n=2) is indicated.  
c Obtained with thrombin thawed from frozen aliquots. Freezing may have 
somewhat reduced the activity of thrombin. 
d
 Average ± SD (n=3) is indicated.  
e No cleavage was detectable 
 
 
Table II 
Calculated enzyme concentrations to produce 3- and 5-hour half-lives for pro-FD 
 
 3 hours 5 hours 
enzyme plasma 
conc. 
 
 
(nM) 
conc. 
of zymogen 
required 
 
(nM) 
conc. 
of active 
enzyme 
required 
(nM) 
conc. 
of zymogen 
required 
 
(nM) 
conc. 
of active 
enzyme 
required 
(nM) 
MASP-1 a 143 3600 16 2100 10 
MASP-2 a 6 ∞ 9 ∞ 5 
MASP-3 a 63 ∞ 14 ∞ 8 
a Total concentration of all forms according to Thiel et al. (29) 
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Table III 
Half-life of labeled pro-FD in serum or plasma in the presence or absence of inhibitors 
matrix pro-FD half-life (hours) 
serum a 2.8 ± 0.5 
serum + 15 µM SGMI-1 b 3.0 ± 0.5 
serum + 15 µM SGMI-2 c 9.0 ± 1.0 
plasma a 4.7 ± 0.5 
plasma + 15 µM SGMI-1 c 5.5 ± 0.5 
plasma + 15 µM SGMI-2 d 17 ± 4 
plasma + 1 µM SGMI-2 b 6.5 ± 0.5 
plasma + 100 nM SGMI-2 a 4.6 ± 0.5 
a Average ± SD (n=5) is indicated. This 0.5 h deviation is considered to be the typical minimal error 
attributable the method. 
b
 Two identical values were obtained, but a deviation of 0.5 h can be assumed, as explained above. 
c
 Average ± range, n=2 is indicated. 
d
 Average ± SD (n=4) is indicated. 
 
 
Table IV 
Half-life of labeled pro-FD in plasma in the presence or absence of exogenously added MASPs 
matrix pro-FD half-life (hours) 
plasma a 4.7 ± 0.5 
plasma + 200 nM MASP-1cf b 5.0 ± 0.5 
plasma + 200 nM MASP-2cf b 5.0 ± 0.5 
plasma + 50 nM MASP-3cf b 2.0 ± 0.5 
plasma + 200 nM MASP-3cf c 0.4 ± 0.1 
a Average ± SD (n=5) is indicated. This 0.5 h deviation is considered to be the typical minimal error 
attributable the method. 
b
 Two identical values were obtained, but a deviation of 0.5 h can be assumed, as explained above. 
c
 Two identical values were obtained by interpolation, but a deviation of about 0.1 h was assumed, 
because of the sampling intensity (every 0.25 h) near the half-life. 
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Supplemental Table I 
 
Synthetic pre-pro-FD-H6 gene sequence, translation and selected restriction sites 
 
Gene (and protein) name Sequence, translation and selected restriction sites 
human pre-pro-FD-H6     PstI 
   1 CTGCAGATGC ACAGCTGGGA GCGCCTGGCA GTTCTGGTCC TCCTAGGAGC 
           M  H   S  W  E   R  L  A   V  L  V  L   L  G  A    
 
  51 GGCCGCCTGC GCGGCGCCGC CCCGTGGTCG GATCCTGGGC GGCAGAGAGG 
      A  A  C   A  A  P  P   R  G  R   I  L  G   G  R  E  A   
 
 101 CCGAGGCGCA CGCGCGTCCC TACATGGCGT CGGTGCAGCT GAACGGCGCG 
       E  A  H   A  R  P   Y  M  A  S   V  Q  L   N  G  A     
 
 151 CACCTGTGCG GCGGCGTCCT GGTGGCGGAG CAGTGGGTGC TGAGCGCGGC 
     H  L  C  G   G  V  L   V  A  E   Q  W  V  L   S  A  A    
 
 201 GCACTGCCTG GAGGACGCGG CCGACGGCAA GGTGCAGGTT CTCCTGGGCG 
      H  C  L   E  D  A  A   D  G  K   V  Q  V   L  L  G  A   
 
 251 CGCACTCCCT GTCGCAGCCG GAGCCCTCCA AGCGCCTGTA CGACGTGCTC 
       H  S  L   S  Q  P   E  P  S  K   R  L  Y   D  V  L     
 
 301 CGCGCAGTGC CCCACCCGGA CAGCCAGCCC GACACCATCG ACCACGACCT 
     R  A  V  P   H  P  D   S  Q  P   D  T  I  D   H  D  L    
 
 351 CCTGCTGCTA CAGCTGTCGG AGAAGGCCAC ACTGGGCCCT GCTGTGCGCC 
      L  L  L   Q  L  S  E   K  A  T   L  G  P   A  V  R  P   
 
 401 CCCTGCCCTG GCAGCGCGTG GACCGCGACG TGGCACCGGG AACTCTCTGC 
       L  P  W   Q  R  V   D  R  D  V   A  P  G   T  L  C     
 
 451 GACGTGGCCG GCTGGGGCAT AGTCAACCAC GCGGGCCGCC GCCCGGACAG 
     D  V  A  G   W  G  I   V  N  H   A  G  R  R   P  D  S    
 
 501 CCTCCAGCAC GTGCTCTTGC CGGTGCTGGA CCGCGCCACC TGCAACCGTC 
      L  Q  H   V  L  L  P   V  L  D   R  A  T   C  N  R  R   
 
 551 GCACGCACCA CGACGGCGCC ATCACCGAGC GCTTGATGTG CGCGGAGAGC 
       T  H  H   D  G  A   I  T  E  R   L  M  C   A  E  S     
 
 601 AATCGCCGTG ACAGCTGCAA GGGTGACTCC GGCGGCCCGC TGGTGTGCGG 
     N  R  R  D   S  C  K   G  D  S   G  G  P  L   V  C  G    
 
 651 CGGCGTGCTC GAGGGCGTGG TCACCTCGGG CTCGCGCGTT TGCGGCAACC 
      G  V  L   E  G  V  V   T  S  G   S  R  V   C  G  N  R   
 
 701 GCAAGAAGCC CGGCATCTAC ACCCGCGTGG CGAGCTATGC GGCCTGGATC 
       K  K  P   G  I  Y   T  R  V  A   S  Y  A   A  W  I     
 
                                            EcoRI 
 751 GACAGCGTCC TGGCCCATCA TCATCATCAT CATTAAGAAT TC         
     D  S  V  L   A  H  H   H  H  H   H  *    
Only the restriction sites used for subcloning are shown (underlined) 
 
 
